A 55-year-old woman with a mechanical mitral valve (on warfarin, INR 2.8) and recent diagnosis of acute coronary syndrome (non-STEMI) presents for coronary angiography. Angiography reveals a critical left anterior descending (LAD) stenosis requiring stent placement. She has no contraindications to dual antiplatelet therapy. Which of the following is the most appropriate antiplatelet loading strategy before PCI?

Explanation

## Clinical Context This patient has a mechanical mitral valve (high thrombotic risk) on warfarin AND acute coronary syndrome requiring PCI. This is a collision of two high-thrombotic-risk conditions, each demanding anticoagulation/antiplatelet therapy. The management principle is: **do not compromise either indication**. ## Rationale for Correct Answer **Key Point:** In mechanical valve + ACS undergoing PCI, triple therapy (warfarin + aspirin + P2Y12 inhibitor) is mandatory. The mechanical valve thrombosis risk is extremely high if anticoagulation is interrupted or inadequate. 1. **Aspirin 300 mg loading** — standard for ACS 2. **Clopidogrel 600 mg loading** — preferred P2Y12 inhibitor in this setting (see comparison below) 3. **Continue warfarin** — NEVER discontinue; mechanical valve requires lifelong anticoagulation. Interruption for even 24 hours increases thrombosis risk significantly 4. **Plan duration:** - Aspirin: lifelong (post-ACS) - Clopidogrel: 12 months (standard post-PCI) - Warfarin: lifelong (mechanical valve) **High-Yield:** The statement "switch to aspirin monotherapy after 1 month" in option 1 is misleading — it should read "continue triple therapy for 12 months, then warfarin + aspirin lifelong." Clopidogrel is NOT stopped at 1 month; it continues for 12 months post-PCI. ## Why Clopidogrel Over Prasugrel or Ticagrelor? | Feature | Clopidogrel | Prasugrel | Ticagrelor | | --- | --- | --- | --- | | Bleeding risk | Moderate | **High** | **High** | | Mechanical valve safety | **Preferred** | Avoid | Avoid | | CYP3A4 interaction | Yes | No | **Yes** | | Reversibility | No | No | No | | **Recommendation** | **First-line** | **Avoid** | **Avoid** | **Clinical Pearl:** Prasugrel and ticagrelor carry significantly higher bleeding risk than clopidogrel. In a patient already on warfarin (high bleeding risk), clopidogrel is the safest P2Y12 inhibitor. Prasugrel is particularly contraindicated due to its potency and bleeding profile. ## Mechanical Valve Thrombosis Risk **Mnemonic: VALVE-CLOT** — Valve mechanical = anticoagulation essential; Antiplatelet alone is insufficient; Lifelong warfarin non-negotiable; Verify INR 2–3 (mitral) or 2.5–3.5 (aortic); Every interruption risks thrombosis. - Mechanical mitral valve: INR target 2–3 (or 2.5–3 if high-risk) - Mechanical aortic valve: INR target 2–3 - Interruption for >24 hours: thrombosis risk rises sharply - Aspirin monotherapy is **insufficient** for mechanical valve protection ## Triple Therapy Bleeding Risk Mitigation - Use clopidogrel (lowest bleeding risk) - Add PPI (gastroprotection) - Target INR 2–2.5 (lower end of therapeutic range for mitral valve) - Avoid NSAIDs - Patient education on bleeding signs - Regular INR and platelet monitoring ## Duration Clarification - **Aspirin + Clopidogrel + Warfarin:** 12 months (post-PCI duration of DAPT) - **Aspirin + Warfarin:** lifelong (after clopidogrel stops at 12 months) [cite:Harrison 21e Ch 297; Robbins 10e Ch 12]